Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Bispecific GRPR-Antagonistic Anti-PSMA/GRPR Heterodimer for PET and SPECT Diagnostic Imaging of Prostate Cancer.

Mitran B, Varasteh Z, Abouzayed A, Rinne SS, Puuvuori E, De Rosa M, Larhed M, Tolmachev V, Orlova A, Rosenström U.

Cancers (Basel). 2019 Sep 14;11(9). pii: E1371. doi: 10.3390/cancers11091371.

2.

Molecular Imaging of Fibroblast Activity After Myocardial Infarction Using a 68Ga-Labeled Fibroblast Activation Protein Inhibitor, FAPI-04.

Varasteh Z, Mohanta S, Robu S, Braeuer M, Li Y, Omidvari N, Topping G, Sun T, Nekolla SG, Richter A, Weber C, Habenicht A, Haberkorn UA, Weber WA.

J Nucl Med. 2019 Dec;60(12):1743-1749. doi: 10.2967/jnumed.119.226993. Epub 2019 Aug 12.

PMID:
31405922
3.

Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 68Ga-NOTA-anti-MMR nanobody: non-invasive imaging of atherosclerotic plaques.

Varasteh Z, Mohanta S, Li Y, López Armbruster N, Braeuer M, Nekolla SG, Habenicht A, Sager HB, Raes G, Weber W, Hernot S, Schwaiger M.

EJNMMI Res. 2019 Jan 21;9(1):5. doi: 10.1186/s13550-019-0474-0.

4.

Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using 111In-tilmanocept.

Varasteh Z, Hyafil F, Anizan N, Diallo D, Aid-Launais R, Mohanta S, Li Y, Braeuer M, Steiger K, Vigne J, Qin Z, Nekolla SG, Fabre JE, Döring Y, Le Guludec D, Habenicht A, Vera DR, Schwaiger M.

EJNMMI Res. 2017 Dec;7(1):40. doi: 10.1186/s13550-017-0287-y. Epub 2017 May 3.

5.

Selection of optimal chelator improves the contrast of GRPR imaging using bombesin analogue RM26.

Mitran B, Varasteh Z, Selvaraju RK, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Rosenström U, Orlova A.

Int J Oncol. 2016 May;48(5):2124-34. doi: 10.3892/ijo.2016.3429. Epub 2016 Mar 9.

PMID:
26983776
6.

Comparative evaluation of 111In-labeled NOTA‑conjugated affibody molecules for visualization of HER3 expression in malignant tumors.

Andersson KG, Rosestedt M, Varasteh Z, Malm M, Sandström M, Tolmachev V, Löfblom J, Ståhl S, Orlova A.

Oncol Rep. 2015 Aug;34(2):1042-8. doi: 10.3892/or.2015.4046. Epub 2015 Jun 9.

PMID:
26059265
7.

The effect of macrocyclic chelators on the targeting properties of the 68Ga-labeled gastrin releasing peptide receptor antagonist PEG2-RM26.

Varasteh Z, Mitran B, Rosenström U, Velikyan I, Rosestedt M, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Orlova A.

Nucl Med Biol. 2015 May;42(5):446-454. doi: 10.1016/j.nucmedbio.2014.12.009. Epub 2014 Dec 20.

PMID:
25684649
8.

Selection of an optimal cysteine-containing peptide-based chelator for labeling of affibody molecules with (188)Re.

Altai M, Honarvar H, Wållberg H, Strand J, Varasteh Z, Rosestedt M, Orlova A, Dunås F, Sandström M, Löfblom J, Tolmachev V, Ståhl S.

Eur J Med Chem. 2014 Nov 24;87:519-28. doi: 10.1016/j.ejmech.2014.09.082. Epub 2014 Sep 26.

9.

188Re-ZHER2:V2, a promising affibody-based targeting agent against HER2-expressing tumors: preclinical assessment.

Altai M, Wållberg H, Honarvar H, Strand J, Orlova A, Varasteh Z, Sandström M, Löfblom J, Larsson E, Strand SE, Lubberink M, Ståhl S, Tolmachev V.

J Nucl Med. 2014 Nov;55(11):1842-8. doi: 10.2967/jnumed.114.140194. Epub 2014 Oct 2.

10.

The effect of mini-PEG-based spacer length on binding and pharmacokinetic properties of a 68Ga-labeled NOTA-conjugated antagonistic analog of bombesin.

Varasteh Z, Rosenström U, Velikyan I, Mitran B, Altai M, Honarvar H, Rosestedt M, Lindeberg G, Sörensen J, Larhed M, Tolmachev V, Orlova A.

Molecules. 2014 Jul 17;19(7):10455-72. doi: 10.3390/molecules190710455.

11.

Gallium-68-labeled affibody molecule for PET imaging of PDGFRβ expression in vivo.

Strand J, Varasteh Z, Eriksson O, Abrahmsen L, Orlova A, Tolmachev V.

Mol Pharm. 2014 Nov 3;11(11):3957-64. doi: 10.1021/mp500284t. Epub 2014 Jul 23.

PMID:
24972112
12.

Imaging of HER3-expressing xenografts in mice using a (99m)Tc(CO) 3-HEHEHE-Z HER3:08699 affibody molecule.

Orlova A, Malm M, Rosestedt M, Varasteh Z, Andersson K, Selvaraju RK, Altai M, Honarvar H, Strand J, Ståhl S, Tolmachev V, Löfblom J.

Eur J Nucl Med Mol Imaging. 2014 Jul;41(7):1450-9. doi: 10.1007/s00259-014-2733-7. Epub 2014 Mar 13.

PMID:
24622956
13.

Imaging of platelet-derived growth factor receptor β expression in glioblastoma xenografts using affibody molecule 111In-DOTA-Z09591.

Tolmachev V, Varasteh Z, Honarvar H, Hosseinimehr SJ, Eriksson O, Jonasson P, Frejd FY, Abrahmsen L, Orlova A.

J Nucl Med. 2014 Feb;55(2):294-300. doi: 10.2967/jnumed.113.121814. Epub 2014 Jan 9.

14.

In vitro and in vivo evaluation of a (18)F-labeled high affinity NOTA conjugated bombesin antagonist as a PET ligand for GRPR-targeted tumor imaging.

Varasteh Z, Aberg O, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Antoni G, Sandström M, Tolmachev V, Orlova A.

PLoS One. 2013 Dec 3;8(12):e81932. doi: 10.1371/journal.pone.0081932. eCollection 2013.

15.

Detecting ligand interactions with G protein-coupled receptors in real-time on living cells.

Xu B, Varasteh Z, Orlova A, Andersson K, Larhammar D, Björkelund H.

Biochem Biophys Res Commun. 2013 Nov 29;441(4):820-4. doi: 10.1016/j.bbrc.2013.10.149. Epub 2013 Nov 6.

PMID:
24211197
16.

Synthesis and characterization of a high-affinity NOTA-conjugated bombesin antagonist for GRPR-targeted tumor imaging.

Varasteh Z, Velikyan I, Lindeberg G, Sörensen J, Larhed M, Sandström M, Selvaraju RK, Malmberg J, Tolmachev V, Orlova A.

Bioconjug Chem. 2013 Jul 17;24(7):1144-53. doi: 10.1021/bc300659k. Epub 2013 Jul 2.

PMID:
23763444
17.

Inhibiting HER3-mediated tumor cell growth with affibody molecules engineered to low picomolar affinity by position-directed error-prone PCR-like diversification.

Malm M, Kronqvist N, Lindberg H, Gudmundsdotter L, Bass T, Frejd FY, Höidén-Guthenberg I, Varasteh Z, Orlova A, Tolmachev V, Ståhl S, Löfblom J.

PLoS One. 2013 May 10;8(5):e62791. doi: 10.1371/journal.pone.0062791. Print 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/0d29f87c-8dfb-4694-abc7-7284a970910d.

18.

In vivo and in vitro studies on renal uptake of radiolabeled affibody molecules for imaging of HER2 expression in tumors.

Altai M, Varasteh Z, Andersson K, Eek A, Boerman O, Orlova A.

Cancer Biother Radiopharm. 2013 Apr;28(3):187-95. doi: 10.1089/cbr.2012.1304. Epub 2013 Mar 5.

PMID:
23461385
19.

[99mTc(CO)3]+-(HE)3-ZIGF1R:4551, a new Affibody conjugate for visualization of insulin-like growth factor-1 receptor expression in malignant tumours.

Orlova A, Hofström C, Strand J, Varasteh Z, Sandstrom M, Andersson K, Tolmachev V, Gräslund T.

Eur J Nucl Med Mol Imaging. 2013 Feb;40(3):439-49. doi: 10.1007/s00259-012-2284-8. Epub 2012 Nov 21.

PMID:
23179942
20.

Comparative evaluation of synthetic anti-HER2 Affibody molecules site-specifically labelled with 111In using N-terminal DOTA, NOTA and NODAGA chelators in mice bearing prostate cancer xenografts.

Malmberg J, Perols A, Varasteh Z, Altai M, Braun A, Sandström M, Garske U, Tolmachev V, Orlova A, Karlström AE.

Eur J Nucl Med Mol Imaging. 2012 Mar;39(3):481-92. doi: 10.1007/s00259-011-1992-9. Epub 2011 Nov 30.

PMID:
22322933

Supplemental Content

Loading ...
Support Center